Clinical Trial

A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a multicenter, open label phase I clinical trial aimed at evaluating the pharmacokinetics, tolerability, safety and immunogenicity of SHR-1316 (sc) subcutaneous administration combined with carboplatin and etoposide as first-line treatment for extensive stage small cell lung cancer, and to observe the initial anti-tumor efficacy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-29; most recent amendment 2026-06-25.
Status change: Recruiting → Active, Not Recruiting 2026-06-25
Status change: Not Yet Recruiting → Recruiting 2025-07-02
Trial Details
NCT Number NCT07009457
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Widespread Small Cell Lung Cancer
Enrollment 24 participants
Start Date 2025-06-16
Primary Completion 2027-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-30